Literature DB >> 22422874

Surgical results and staging of non-small cell lung cancer with interlobar pleural invasion.

Ryu Kanzaki1, Naoki Ikeda, Eiji Okura, Naoto Kitahara, Yasushi Shintani, Akira Okimura, Kunimitsu Kawahara, Mitsunori Ohta.   

Abstract

The aim of this study was to compare the survival rates of non-small cell lung cancer (NSCLC) with interlobar pleural invasion (IPI) with that of patients with other T2 and T3 diseases according to the seventh TNM staging system. One thousand and one patients with pathologic T2 and T3 NSCLC (according to the seventh staging criteria) treated between 1980 and 2004 were retrospectively evaluated. Among these, 682 patients were pathologically staged as T2 without IPI (T2 group), 25 as T2 with IPI (IPI group) and 294 as T3 (T3 group). The 5-year survival rate for the T2, IPI and T3 groups were 52.0, 31.1 and 36.3%, respectively. In patients without nodal involvement, the 5-year survival rates of the T2N0, IPIN0 and T3N0 groups were 60.9, 40.0 and 45.9%, respectively. The survival rate was significantly different between the T3N0 and T2N0 groups (P < 0.001) and between the IPIN0 and T2N0 (P = 0.020) groups. There was no significant difference in the survival rate between the IPIN0 and T3N0 groups (P = 0.644). In patients without nodal involvement, the survival of NSCLC with IPI is similar to that of the T3 disease.

Entities:  

Mesh:

Year:  2012        PMID: 22422874      PMCID: PMC3352743          DOI: 10.1093/icvts/ivs094

Source DB:  PubMed          Journal:  Interact Cardiovasc Thorac Surg        ISSN: 1569-9285


  8 in total

1.  How should interlobar pleural invasion be classified? Prognosis of resected T3 non-small cell lung cancer.

Authors:  M Okada; N Tsubota; M Yoshimura; Y Miyamoto; H Matsuoka
Journal:  Ann Thorac Surg       Date:  1999-12       Impact factor: 4.330

2.  Clinical upstaging of non-small cell lung cancer that extends across the fissure: implications for non-small cell lung cancer staging.

Authors:  Vijay Joshi; James McShane; Richard Page; Martyn Carr; Neeraj Mediratta; Michael Shackcloth; Michael Poullis
Journal:  Ann Thorac Surg       Date:  2011-02       Impact factor: 4.330

3.  Cancer statistics, 2007.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Taylor Murray; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2007 Jan-Feb       Impact factor: 508.702

4.  Invasion beyond interlobar pleura in non-small cell lung cancer.

Authors:  H Miura; O Taira; O Uchida; H Kato
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

5.  Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer.

Authors:  William D Travis; Elisabeth Brambilla; Ramon Rami-Porta; Eric Vallières; Masahiro Tsuboi; Valerie Rusch; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2008-12       Impact factor: 15.609

Review 6.  The revised TNM staging system for lung cancer.

Authors:  Ramon Rami-Porta; John J Crowley; Peter Goldstraw
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-02       Impact factor: 1.520

7.  Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers.

Authors:  Takayuki Fukui; Shoichi Mori; Shunzo Hatooka; Masayuki Shinoda; Tetsuya Mitsudomi
Journal:  J Thorac Cardiovasc Surg       Date:  2008-08-15       Impact factor: 5.209

8.  Staging and resection of lung cancer with minimal invasion of the adjacent lobe.

Authors:  Adalet Demir; Mehmet Zeki Gunluoglu; Deniz Sansar; Huseyin Melek; Seyyit Ibrahim Dincer
Journal:  Eur J Cardiothorac Surg       Date:  2007-11-01       Impact factor: 4.191

  8 in total
  2 in total

1.  Is adjacent lobe invasion an T category upgrade factor for resected non-small cell lung cancer ≤ 5 cm?

Authors:  Jing-Sheng Cai; Qian-Yi Lin; Xiao-Meng Dou
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-21       Impact factor: 4.553

2.  Should tumor with direct adjacent lobe invasion (Tdali) be assigned to T2 or T3 in non-small cell lung cancer: a meta-analysis.

Authors:  Zhilan Xiao; Christphor Cao; Jiandong Mei; Hu Liao; Tristan Yan; Lunxu Liu
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.